Get started
Work

Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson’s disease and its comorbidities

Year: 2024
Type: article
Abstract: receptor is proposed. The compound PZKKN-94 produces an antiparkinsonian-like effect and attenuates motor fluctuations, preserving the efficacy of L-DOPA. In addition, PZKKN-94 demonstrates procognitive and antidepressant-like properties.
DOI: 10.1016/j.jpet.2024.100055
Authors: Paweł Zajdel, Mikołaj Matłoka, Jolanta Konieczny, Tomasz Kos, Josie C. Lammers, Natalie G. Cavalco, Allison A. Clark, Tomasz Lenda, Grzegorz Satała, Vittorio Canale, Katarzyna Grychowska, Martyna Krawczyk, Agnieszka Nikiforuk, Anna Partyka, Magdalena Jastrzębska-Więsek, Klemencja Berghauzen-Maciejewska, Dominika Biała, Monika Janicka, Artur Janusz, Radosław Piast, Krzysztof Mulewski, Damian Smuga, Jerzy Pieczykolan, Maciej Wieczorek, Rafał Moszczyński-Pętkowski, Krzysztof Dubiel, Krystyna Ossowska, Andrzej J. Bojarski, Krzysztof Kamiński, John D. McCorvy, Piotr Popik
Institutions: Jagiellonian University, Celon Pharma (Poland), Maj Institute of Pharmacology, Polish Academy of Sciences, Medical College of Wisconsin, Medical College of Wisconsin Cancer Center
Language: English
Subfield: Neurology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,750
OpenAlex ID: W4405175752
FWCI: 1.834
Cites: 59
Cited by: 8
Related to: 10